Takeda Terminates DNL593 Collaboration with Denali
Analysis based on 8 articles · First reported Apr 03, 2026 · Last updated Apr 03, 2026
The market impact is positive for Denali Therapeutics as it regains full control of DNL593, a promising therapy for FTD-GRN, potentially increasing its long-term value. For Takeda Pharmaceutical Company, the impact is neutral as the termination was strategic and not related to the drug's efficacy or safety.
Takeda Pharmaceutical Company has terminated its collaboration agreement with Denali Therapeutics to co-develop and co-commercialize DNL593, an investigational progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN). This decision, announced on April 3, 2026, was driven by strategic considerations and was not related to the efficacy or safety data of DNL593. As a result, Denali Therapeutics has regained full control of DNL593 and its intellectual property portfolio. Ryan Watts, CEO of Denali Therapeutics, expressed confidence in the scientific rationale and data generated to date for DNL593, stating that the company plans to advance the therapy independently. Results from the ongoing Phase 1/2 study of DNL593, which has completed enrollment with 40 participants, are expected by the end of 2026. Interim results from an earlier part of the study in healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin levels, indicating robust brain delivery, and DNL593 was generally well tolerated with no significant safety signals.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard